MX2019012942A - Compuestos de imidazo-piperidina fusionada como inhibidores de jak. - Google Patents
Compuestos de imidazo-piperidina fusionada como inhibidores de jak.Info
- Publication number
- MX2019012942A MX2019012942A MX2019012942A MX2019012942A MX2019012942A MX 2019012942 A MX2019012942 A MX 2019012942A MX 2019012942 A MX2019012942 A MX 2019012942A MX 2019012942 A MX2019012942 A MX 2019012942A MX 2019012942 A MX2019012942 A MX 2019012942A
- Authority
- MX
- Mexico
- Prior art keywords
- jak inhibitor
- compound
- inhibitor compound
- piperidine
- fused imidazo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 229940122245 Janus kinase inhibitor Drugs 0.000 title abstract 3
- AIAJYBLPGVBVSS-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-imidazo[4,5-b]pyridine Chemical compound C1CCNC2=C1NC=N2 AIAJYBLPGVBVSS-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Un compuesto de fórmula 1 (ver fórmula 1) o una sal farmacéuticamente aceptable del mismo, útil como inhibidor de JAK. La invención también provee formas cristalinas del compuesto, composiciones farmacéuticas que comprenden tal compuesto, métodos para usar el compuesto para tratar enfermedades susceptibles a un inhibidor de JAK, y procesos e intermediarios útiles para preparar el compuesto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762492574P | 2017-05-01 | 2017-05-01 | |
PCT/US2018/030148 WO2018204238A1 (en) | 2017-05-01 | 2018-04-30 | Fused imidazo-piperidine jak inhibitor compound |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019012942A true MX2019012942A (es) | 2019-12-16 |
Family
ID=62165730
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019012942A MX2019012942A (es) | 2017-05-01 | 2018-04-30 | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. |
Country Status (31)
Country | Link |
---|---|
US (3) | US10493077B2 (es) |
EP (1) | EP3601283B1 (es) |
JP (1) | JP7098656B2 (es) |
KR (1) | KR102550225B1 (es) |
CN (1) | CN110573508B (es) |
AR (1) | AR111495A1 (es) |
AU (1) | AU2018261593B2 (es) |
BR (1) | BR112019022648A2 (es) |
CA (1) | CA3056283A1 (es) |
CL (1) | CL2019003086A1 (es) |
CO (1) | CO2019011809A2 (es) |
CY (1) | CY1125051T1 (es) |
DK (1) | DK3601283T3 (es) |
EA (1) | EA201992601A1 (es) |
ES (1) | ES2908756T3 (es) |
HR (1) | HRP20220330T1 (es) |
IL (1) | IL270231B2 (es) |
LT (1) | LT3601283T (es) |
MA (1) | MA47970B1 (es) |
MD (1) | MD3601283T2 (es) |
MX (1) | MX2019012942A (es) |
NZ (1) | NZ757570A (es) |
PH (1) | PH12019502264A1 (es) |
PL (1) | PL3601283T3 (es) |
PT (1) | PT3601283T (es) |
RS (1) | RS62995B1 (es) |
SG (1) | SG11201908604YA (es) |
SI (1) | SI3601283T1 (es) |
TW (1) | TWI760486B (es) |
UA (1) | UA124478C2 (es) |
WO (1) | WO2018204238A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3371186A1 (en) | 2015-11-03 | 2018-09-12 | Theravance Biopharma R&D IP, LLC | Jak kinase inhibitor compounds for treatment of respiratory disease |
EP3592742B1 (en) | 2017-03-09 | 2021-05-19 | Theravance Biopharma R&D IP, LLC | Jak inhibitors containing a 4-membered heterocyclic amide |
KR102568333B1 (ko) | 2017-05-01 | 2023-08-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 저해제 화합물을 사용하는 치료 방법 |
AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
ES2955717T3 (es) | 2018-09-04 | 2023-12-05 | Theravance Biopharma R&D Ip Llc | Amidas heterocíclicas de 5 a 7 elementos como inhibidores de JAK |
LT3837258T (lt) | 2018-09-04 | 2024-05-27 | Theravance Biopharma R&D Ip, Llc | Dimetilamino azetidino amidai kaip jak inhibitoriai |
MX2021002273A (es) | 2018-09-04 | 2021-05-27 | Theravance Biopharma R&D Ip Llc | Proceso para preparar inhibidores de las jak y productos intermedios de estos. |
MX2021004582A (es) | 2018-10-29 | 2021-06-15 | Theravance Biopharma R&D Ip Llc | Compuesto 2-azabiciclo hexano inhibidor de jak. |
EP3908278A4 (en) | 2019-01-11 | 2022-09-28 | Naegis Pharmaceuticals Inc. | LEUCOTRIENE SYNTHESIS INHIBITORS |
JP2022523274A (ja) * | 2019-02-25 | 2022-04-21 | ホーナン メディノ ファーマシューティカル テクノロジー カンパニー リミテッド | Jak阻害剤化合物及びその使用 |
EP3934651A1 (en) | 2019-03-05 | 2022-01-12 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
EP3942045A1 (en) | 2019-03-21 | 2022-01-26 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
TW202144343A (zh) | 2020-03-02 | 2021-12-01 | 美商施萬生物製藥研發 Ip有限責任公司 | Jak抑制劑化合物之結晶水合物 |
WO2021185305A1 (zh) * | 2020-03-18 | 2021-09-23 | 四川海思科制药有限公司 | 一种吲唑衍生物及其在医药上的应用 |
CN111620868B (zh) * | 2020-05-28 | 2021-08-31 | 爱斯特(成都)生物制药股份有限公司 | 一种1H-吡唑并[3,4-b]吡啶-3-甲醛的制备方法 |
WO2022272020A1 (en) * | 2021-06-25 | 2022-12-29 | Theravance Biopharma R&D Ip, Llc | Imidazolo indazole compounds as jak inhibitors |
CN114181055A (zh) * | 2021-12-21 | 2022-03-15 | 苏州楚凯药业有限公司 | 1-苄氧基-4-溴-5-乙基-2-氟苯的制备方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
US8648069B2 (en) | 2007-06-08 | 2014-02-11 | Abbvie Inc. | 5-substituted indazoles as kinase inhibitors |
JP2010111624A (ja) | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ttk阻害作用を有するインダゾール誘導体 |
WO2010114971A1 (en) | 2009-04-03 | 2010-10-07 | Sepracor Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
BR112012018413A2 (pt) | 2009-12-21 | 2016-08-09 | Samumed Llc | 1h-pirazol[3,4-b]piridinas e usos terapêuticos dos mesmos. |
US8575336B2 (en) * | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
MD4649C1 (ro) | 2013-12-05 | 2020-04-30 | Pfizer Inc. | Pirol[2,3-d]pirimidinil, pirol[2,3-b]pirazinil şi pirol[2,3-d]piridinil acrilamide |
EP3143021B1 (en) | 2014-05-14 | 2019-06-12 | Pfizer Inc | Pyrazolopyridines and pyrazolopyrimidines |
WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
KR101663277B1 (ko) | 2015-03-30 | 2016-10-06 | 주식회사 녹십자 | TNIK, IKKε 및 TBK1 억제제로서의 피라졸계 유도체 및 이를 포함하는 약학적 조성물 |
EP3865481A1 (en) | 2015-11-03 | 2021-08-18 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
EP3371186A1 (en) | 2015-11-03 | 2018-09-12 | Theravance Biopharma R&D IP, LLC | Jak kinase inhibitor compounds for treatment of respiratory disease |
EP3371185B1 (en) | 2015-11-03 | 2020-09-30 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
EP3592742B1 (en) | 2017-03-09 | 2021-05-19 | Theravance Biopharma R&D IP, LLC | Jak inhibitors containing a 4-membered heterocyclic amide |
CA3059790A1 (en) | 2017-05-01 | 2018-11-08 | Theravance Biopharma R&D Ip, Llc | Crystalline forms of a jak inhibitor compound |
KR102568333B1 (ko) | 2017-05-01 | 2023-08-18 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Jak 저해제 화합물을 사용하는 치료 방법 |
AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
-
2018
- 2018-04-27 AR ARP180101103A patent/AR111495A1/es unknown
- 2018-04-30 ES ES18724754T patent/ES2908756T3/es active Active
- 2018-04-30 SG SG11201908604Y patent/SG11201908604YA/en unknown
- 2018-04-30 CN CN201880028413.7A patent/CN110573508B/zh active Active
- 2018-04-30 LT LTEPPCT/US2018/030148T patent/LT3601283T/lt unknown
- 2018-04-30 EA EA201992601A patent/EA201992601A1/ru unknown
- 2018-04-30 SI SI201830589T patent/SI3601283T1/sl unknown
- 2018-04-30 UA UAA201911546A patent/UA124478C2/uk unknown
- 2018-04-30 PT PT187247549T patent/PT3601283T/pt unknown
- 2018-04-30 MD MDE20200142T patent/MD3601283T2/ro unknown
- 2018-04-30 US US15/966,467 patent/US10493077B2/en active Active
- 2018-04-30 NZ NZ757570A patent/NZ757570A/en not_active IP Right Cessation
- 2018-04-30 RS RS20220238A patent/RS62995B1/sr unknown
- 2018-04-30 CA CA3056283A patent/CA3056283A1/en active Pending
- 2018-04-30 EP EP18724754.9A patent/EP3601283B1/en active Active
- 2018-04-30 TW TW107114647A patent/TWI760486B/zh active
- 2018-04-30 MA MA47970A patent/MA47970B1/fr unknown
- 2018-04-30 JP JP2019559297A patent/JP7098656B2/ja active Active
- 2018-04-30 MX MX2019012942A patent/MX2019012942A/es unknown
- 2018-04-30 DK DK18724754.9T patent/DK3601283T3/da active
- 2018-04-30 BR BR112019022648A patent/BR112019022648A2/pt unknown
- 2018-04-30 AU AU2018261593A patent/AU2018261593B2/en active Active
- 2018-04-30 WO PCT/US2018/030148 patent/WO2018204238A1/en unknown
- 2018-04-30 KR KR1020197035134A patent/KR102550225B1/ko active IP Right Grant
- 2018-04-30 PL PL18724754T patent/PL3601283T3/pl unknown
- 2018-04-30 HR HRP20220330TT patent/HRP20220330T1/hr unknown
-
2019
- 2019-09-30 PH PH12019502264A patent/PH12019502264A1/en unknown
- 2019-10-18 US US16/656,940 patent/US11160810B2/en active Active
- 2019-10-24 CO CONC2019/0011809A patent/CO2019011809A2/es unknown
- 2019-10-28 CL CL2019003086A patent/CL2019003086A1/es unknown
- 2019-10-28 IL IL270231A patent/IL270231B2/en unknown
-
2021
- 2021-09-28 US US17/449,131 patent/US20220008428A1/en active Pending
-
2022
- 2022-03-09 CY CY20221100192T patent/CY1125051T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019012942A (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
PH12019501985A1 (en) | Fused imidazo-piperidine jak inhibitors | |
MX2021004582A (es) | Compuesto 2-azabiciclo hexano inhibidor de jak. | |
PH12018500828A1 (en) | Jak kinase inhibitor compounds for treatment of respiratory disease | |
PH12020500528A1 (en) | Pyrimidine compound as jak kinase inhibitor | |
PH12017502050B1 (en) | Naphthyridine compounds as jak kinase inhibitors | |
SG10201811384TA (en) | Mnk inhibitors and methods related thereto | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
MX2018013191A (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
MX2021015935A (es) | Formas de sal de acido bempedoico y metodos para utilizar el mismo. | |
SG10201902206QA (en) | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof | |
PH12018500268A1 (en) | 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors | |
PH12021550388A1 (en) | Process for preparing jak inhibitors and intermediates thereof | |
PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
MX2019007629A (es) | Proceso para la preparacion de un derivado de 2-piridiletilcarboxamida. | |
EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
NZ765435A (en) | Polymorphs | |
MX2021006692A (es) | Proceso mejorado para preparar ozanimod. | |
EP4289844A3 (en) | A process for making palbociclib |